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Edited by Gerald Hart
Diseases of the glomerular basement membrane (GBM),
such as Goodpasture’s disease (GP) and Alport syndrome (AS),
are a major cause of chronic kidney failure and an unmet
medical need. Collagen IVα345 is an important architectural
element of the GBM that was discovered in previous research
on GP and AS. How this collagen enables GBM to function as a
permselective filter and how structural defects cause renal
failure remain an enigma. We found a distinctive genetic
variant of collagen IVα345 in both a familial GP case and four
AS kindreds that provided insights into these mechanisms. The
variant is an 8-residue appendage at the C-terminus of the α3
subunit of the α345 hexamer. A knock-in mouse harboring the
variant displayed GBM abnormalities and proteinuria. This
pathology phenocopied AS, which pinpointed the α345 hex-
amer as a focal point in GBM function and dysfunction.
Crystallography and assembly studies revealed underlying
hexamer mechanisms, as described in Boudko et al. and Ped-
chenko et al. Bioactive sites on the hexamer surface were
identified where pathogenic pathways of GP and AS converge
and, potentially, that of diabetic nephropathy (DN). We
conclude that the hexamer functions include signaling and
organizing macromolecular complexes, which enable GBM
assembly and function. Therapeutic modulation or replace-
ment of α345 hexamer could therefore be a potential treatment
for GBM diseases, and this knock-in mouse model is suitable
for developing gene therapies.
Diseases of the glomerular basement membrane (GBM)
are a major cause of chronic kidney disease, a health
problem affecting about 10% of the global population and
an unmet medical need (1, 2). Prominent diseases are
diabetic nephropathy (DN), Alport syndrome (AS), and
Goodpasture’s disease (GP) that are characterized by
morphological abnormalities in GBM, ranging from
thickening in DN to multilamellations in AS and ruptures
due to specific GBM attack by antibodies in GP (3–5).
These abnormalities involve structural alterations in
collagen IV, the major GBM component. How collagen IV
enables GBM to function as a permselective filter and how
its structural alterations cause GBM abnormalities and
dysfunction remain an enigma. New insights into these
mysteries were revealed in the present study of a
distinctive genetic variant of collagen IV, uniquely
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associated with both AS and GP diseases, coupled with
crystallography and animal studies.
Collagen IV is a family of six homologous α-chains,
which are distributed within basement membranes (BMs)
that underlie the epithelial architecture of the nephron. In
pioneering studies of the GBM over 50 years ago, collagen
IV was identified as a novel collagen and shown to be
structurally altered in DN (6–12). It was first characterized
as a supramolecular network of triple helical protomers
composed of α1 and α2 chains (13, 14). In subsequent
studies of the GBM in GP and AS, four additional chains
were discovered (α3, α4, α5, and α6) (4, 15–21). The six α-
chains coassemble into protomers with three distinct mo-
lecular compositions: α121, α345, and α565, which in turn
assemble into three distinct supramolecular scaffolds, noted
as collagen IVα121, collagen IVα345, and collagen IVα556 (22,
23). In the nephron, collagen IVα121 occurs in the GBM,
mesangial matrix, Bowman’s capsule BM, and BMs of tu-
bules and capillaries, whereas collagen IVα345 is restricted
to the GBM (24). Moreover, the collagen IVα345 scaffold is
structurally altered in both AS and GP (16–21), kidney
diseases that have served as vanguards for advancing
knowledge of structure, function, and dysfunction of the
GBM (25), as well as other BMs across the animal kingdom
(26).
In GP, an acquired sporadic disorder, autoantibodies
target neoepitopes in the α345 NC1 hexamer that connect
triple helical protomers in the collagen IVα345 scaffold of
GBM and alveolar BM (4, 27–33). The autoantibodies alter
and break the GBM, causing crescentic injury, manifesting as
rapidly progressive glomerulonephritis, often in association
with pulmonary hemorrhage, in thousands of people
worldwide. The etiology of GP remains unknown but is
proposed to be a combination of environmental and genetic
factors, eliciting both humoral and cellular autoimmune
response (34). Current therapy is limited to plasmaphereses
and immunosuppression (35) and, if not initiated at an early
disease stage, is often ineffective to prevent end-stage renal
failure.
In AS, hundreds of genetic variants are now known in
the COL4A3, COL4A4, and COL4A5 genes, encoding the
three α-chains (36–39). These pathogenic variants cause
GBM abnormalities that underlie a broad array of
glomerular phenotypes in millions of people worldwide,
ranging from microscopic hematuria to end-stage kidney
failure (37, 40). How this plethora of variants causes renal
failure remains unknown, which posits a fundamental
question “how does the collagen IVα345 scaffold enable
GBM function?” Lack of clarity in answering this question
impedes the development of therapies (37). Current
treatments have been limited mainly to ACE inhibitors or
ARBs that delay progression to renal failure and the need
for renal transplant (36, 37, 41).
The development of therapy for these GBM diseases
requires knowledge of the pathobiology of the collagen
IVα345 scaffold in relation to structure, assembly, function,
and dysfunction. To this end, a variant in the COL4A3
gene that was found in both a familial GP case and four
kindreds of AS provided a unique opportunity to elucidate
pathogenic mechanisms of these two GBM diseases.
Results
A distinctive variant of α3(IV) collagen (Zurich (Z)-variant) was
found in familial GP and Alport patients
Clinical histories of two patients with familial GP disease
harboring the Z-variant
A 24-year-old man (T.A.) presented with pulmonary-renal
syndrome. His serum was positive for anti-GBM antibodies
at 151 U/ml (reference range: <10 U/ml). The patient required
mechanical ventilation and hemodialysis. Whereas pulmonary
function completely recovered after treatment with plasma-
pheresis, glucocorticoids, and cyclophosphamide, the patient
remained dialysis-dependent. His mother (A.A.) had suffered
fromGP at the age of 45 years also with pulmonary-renal
syndrome, resulting in end-stage kidney disease and a trans-
plant. Anti-GBM antibodies at her initial presentation were
positive at 72 U/ml, and her native kidney biopsy exhibited
severe crescentic glomerulonephritis involving all 23 glomeruli
and linear GBM immunofluorescence staining for IgG and
complement C3 along the GBM. Given the acute situation
with severe crescentic glomerulonephritis, electron micro-
scopy showed no lamellation, thinning, or basket-weaving
pattern of the GBM (Fig. S1). She eventually required renal
transplantation and currently has severely decreased kidney
function. Both patients harbor the HLA allomorph HLA-
DR15, known to be a risk factor of GP, and both had normal
hearing and ophthalmologic examination. No other family
members were affected. Additional clinical details are
described in Supplementary Section 1. By indirect ELISA, the
autoantibodies from the index patient T.A. displayed similar
specificity to autoantibodies from sporadic GP patients with
reactivity restricted to the α3NC1 domain and increased
binding to denatured GBM NC1 hexamer (Fig. 1, A–C).
Given that both mother and son had GP disease, a genetic
defect was hypothesized. Next-generation sequencing revealed
a heterozygous COL4A3 variant (rs765655100) in both pa-
tients located in exon 52, corresponding to the α3NC1 domain
(42) (named herein as Zurich variant). The 18-base pair
deletion included the stop codon and resulted in the replace-
ment of the last amino acid residue by eight additional amino
acids, named herein as the Zurich (Z-) appendage, onto the C-
terminal end of the α3NC1 domain (Fig. 1, E–H,
Supplementary Section 2). We assessed whether the Z-
appendage itself constituted a neoepitope for GP autoanti-
bodies using serum from the index patient. The appendage,
attached to the α3NC1 monomer, did not affect the binding of
GP antibodies and did not bind antibodies when attached to a
α1NC1 monomer, which is inert to antibody binding (Fig. 1D).
These results indicate that the Z-appendage does not comprise
a neoepitope for GP autoantibodies of the index patient.
To determine whether the Zurich variant is present in
sporadic GP patients, we performed targeted sequencing of
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Figure 1. Immunochemical and genetic analyses of index patient with Zurich variant. A, binding of T.A. circulating autoantibodies is restricted to the
α3NC1 domain of human collagen IV, while pooled serum from eight sporadic GP cases (GPc) also reacted to α5NC1. Normal human serum does not react
to any of NC1 domains as depicted by the dashed line (mean plus 3 × SD). B, index patient autoantibodies bind immunodominant epitopes EA and EB of
α3NC1, but not the parental α1NC1 domain used to create α1/α3 chimeric proteins bearing EA and EB epitopes. C, serum from the index patient reacts with
denatured (D), but not native (N) NC1 hexamers purified from human (hGBM) and bovine (bGBM) glomerular basement membrane (left panel). This pattern
is identical to the reactivity of pooled serum of eight sporadic GP patients (right panel). NC1 hexamer from bovine placenta (bPBM), which is composed of
GP nonreactive α1 and α2NC1 subunits served as negative control. D, the Zurich variant does not directly affect antigenicity of the α3NC1 monomer. Serum
from the index patient and from three sporadic GP patients (GP-1, GP-2, GP-3) displayed similar reactivity to the α3NC1 domain and α3NC1 domain variant
(α3-Z), but does not react with either α1NC1 domain or α1NC1 chimera (α1-Z) bearing the eight residues extension from the α3NC1 variant of the index
patient. These results suggest that Zurich appendage does not represent a neoepitope for patient autoantibodies or affect the presentation of immu-
nodominant EA and EB epitopes in the α3NC1 monomer. All bar graphs with T bars (A–D) indicate the means and standard errors. E, a heterozygous COL4A3
variant (rs765655100: c.5010_*del(p.His1670_*167delinsGln*9)) was discovered by next-generation sequencing in two patients with familial Goodpasture’s
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261 cases from five cohorts, which revealed the absence of the
Zurich variant in these patients (Fig. 2A and Supplementary
Section 3.1). Also, the variant was absent in three patients
from a previously reported kindred of familial GP (43)
(Supplementary Section 3.2; Fig. S2, Table S1). However, the
Zurich variant was found in a general population database
(gnomAD; 16 out of ca. 124,000 individuals) of individuals
with unknown health profile and in a clinical database (NCBI
ClinVar; 32 cases out of ca. 100,000 individuals)
(Supplementary Section 3.3). Extrapolation of the gnomAD
database resulted in an estimate of about one million people
worldwide harboring the Zurich variant (Fig. 2A).
Clinical histories of patients with Alport syndrome harboring the
Z-variant
The Z-variant was also identified in six non-GP individuals
with variable renal phenotypes. These individuals were iden-
tified in a cohort of patients subjected to targeted Next-
Generation Sequencing of COL4A3, COL4A4, and COL4A5
genes as part of commercial genetic screening panels
(nephrotic syndrome, focal segmental glomerulosclerosis
(FSGS), and AS) or evaluation of other suspected genetic renal
diseases. In total, COL4A3 sequencing was performed in 1631
patients: in 311 as part of the nephrotic syndrome panel, in 606
as part of the FSGS panel, in 579 as part of the Alport panel,
and in 135, COL4A3 sequencing was included for other sus-
pected genetic renal diseases. Of note, only a minority of these
patients (188) had a histologically confirmed diagnosis. In
summary, the rs765655100 Z-variant was identified in a total
of six individuals from four families (K, H, U, and S) of diverse
origins, with variable renal phenotypes ranging from normal or
asymptomatic microhematuria to end-stage kidney disease
(Figs. S3 and S4; Table S3). Based on the recently proposed
nomenclature of variants in COL4A3, A4, or A5 genes (37),
these six patients, described below, were classified as having
AS.
In family K (Greek origin), the index patient presented at
the age of 23 years with advanced renal failure (creatinine
11.8 mg/dl) and hypertension. By ultrasound, both kidneys
were small, consistent with end-stage kidney disease.
Therefore, he did not undergo renal biopsy. Proteinuria was
1.9 g/g creatinine at presentation, and he did not have he-
maturia. Dialysis was initiated shortly after presentation in
May 2016. His family history was negative for renal disease
including hematuria. Due to sensorineural deafness of the
patient as well as his father, an Alport genetic panel was
ordered as part of the pretransplant evaluation. Both the
patient and his father carried the rs765655100 variant. The
father had normal renal function (creatinine 0.9 mg/dl, eGFR
95 ml/min/1.73 m2), no proteinuria, no hematuria, and his
hearing loss had been previously attributed to job-related
noise exposure.
In family H (Arabic origin), the Alport genetic panel was
ordered due to microhematuria (50 erythrocytes/μl) in a 10-
year-old girl with normal renal function (creatinine 42 μmol/
l) and no proteinuria. The girl’s mother also has asymptomatic
microhematuria but no proteinuria and normal renal function.
Her father suffers from recurrent urolithiasis, but has normal
renal function, no proteinuria, and no microhematuria except
during symptomatic kidney stone episodes. The rs765655100
variant was found in the daughter and her father (who has no
hematuria) but not in the mother (who has microhematuria),
while an additional COL4A4 variant (c.1321_1369+3del, pre-
viously associated with familial hematuria/AS) was identified
in the daughter and her mother, but not in the father. Neither
the index patient nor her parents reported hearing problems.
In family U (mother Caucasian, father Turkish), a 7-year-old
girl with normal renal function (creatinine 0.37 mg/dl) and
microhematuria (150 erythrocytes/μl) but no proteinuria
(urinary protein 86 mg/g creatinine; urinary albumin <20 mg/
g creatinine) with a family history of microhematuria in her
sister, her mother, and her maternal grandfather was tested by
the NGS Alport panel, revealing the heterozygous
rs765655100 variant. The index patient and all family mem-
bers affected by microhematuria have normal hearing.
In family S (Turkish origin), the female index patient
showed microhematuria and mild proteinuria but no abnormal
albuminuria (urinary protein 260 mg/g creatinine; urinary al-
bumin 7 mg/g creatinine) with normal renal function (creati-
nine 0.4 mg/dl, eGFR 143 ml/min/1.73 m2), first detected at
age of 27 years during her second pregnancy. Because her
mother reportedly had microhematuria, the index patient was
tested with the Alport panel, and the rs765655100 variant was
detected without other changes in the tested genes. The index
patient and her mother reportedly have normal hearing.
We also performed HLA typing in all patients and family
members bearing the rs765655100 COL4A3 variant, and none
of them carried the GP risk HLA allele DRB1*15:01. Of note,
none of the four index patients underwent renal biopsy—either
due to advanced chronic renal failure (family K) or due to mild
disease. Pedigree trees are presented in Figure. S3
(Supplementary Section 4).
Importance of the Z-variant in understanding pathogenesis in GP
and AS
About 1700 Alport variants are known in the COL4A3,
COL4A4, and COL4A5 genes; two are distinct with extensions,
termed herein as appendages, onto the C-terminal of the NC1
domains. The Z-variant in the COL4A3 gene encodes an 8-
residue appendage onto the a3NC1 domain and a COL4A5
disease and designated as Zurich variant. The variant produces a C-terminal modification of the collagen IV α3 chain via deletion of 18 base pairs including
the stop codon in exon 52 of COL4A3. This results in an alternative stop codon and a consecutive 8-amino acid protein extension named Z-appendage. F,
the 18 bp in-frame deletion at the C-terminus of NC1 domain introduced an H to Q substitution and added an 8-amino acid appendage to the protein. G
and H, this deletion is flanked by two direct DNA repeats AAAAGACA, suggesting homologous recombination as the mechanism and supporting the
possibility of recurrent mutations at this site. Deletions at sites of direct repeats in various genes, including COL4A3, have been previously reported and
attributed to slippage replication errors (57, 58).
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Figure 2. A genetic variant of α3(IV) collagen (Zurich variant) associated with familial Goodpasture’s disease and Alport syndrome is distinct
among the 1700 known Alport variants. A, Zurich variant is associated with both familial Goodpasture’s disease (GP) and Alport syndrome. This variant
was a risk factor in developing familial Goodpasture’s disease in two Zurich patients (red pie chart wedge and red circle, n = 2). In several cohorts of GP
patients from different countries, the presence of Zurich variant was not detected either by Sanger sequencing of exons 48 to 52 (Switzerland, n = 11;
Sweden, n = 15; China, n = 171; and UK, n = 29) or whole exome/genome sequencing (USA, n = 36) as shown in the gray pie chart. However, the Zurich
variant was detected in patients diagnosed with familial hematuria or suspected Alport syndrome (tan circle, n = 6) and in the general population with
unknown phenotype (dark blue circle, n = 48). The extrapolation of the data set to the world population resulted in estimated one million people carrying
the Zurich variant, and thus classified as Alport Syndrome. Therefore, the Zurich variant places them at risk of progressing to renal failure and developing
Goodpasture’s disease (light blue circle). B, the number and location of 1700+ genetic Alport-associated variants (indicated by yellow dots, zoom in to see
individual dots) in the α3, α4, and α5 chains of collagen IV (left). Pathogenic variants cause either loss of α345 protomers from the GBM or assembly of
defective α345 protomers that can incorporate into the GBM, causing a broad spectrum of GBM phenotypes. Significant numbers of Alport-associated
variants occur within α3, α4, and α5 NC1 domains (right). Zurich variant α3NC1 monomer with an 8-amino acid Z-appendage is shown at top right.
Analogous to Zurich variant, a novel variant α5NC1 monomer with a C-terminal 74-amino acid appendage (59) is shown at bottom right. Because these two
variants resulted in a C-terminal extension of the protein polypeptide chain, they stood out among over 1700 known variants in the COL4A3, COL4A4, and
COL4A5 genes associated with Alport syndrome. The Z-appendage incorporated into the collagen IV scaffold of the GBM and served as a pathogenic
reporter group that identified a new therapeutic target (vide infra).
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variant encodes a 74-residue on the α5NC1 domain (Fig. 2B).
Importantly, the Z-appendage is distinct among the hundreds
of variants for several reasons: 1) it occurred in patients with
AS and in patients with familial GP disease and therefore,
could provide insights into the pathogenesis of both diseases.
2) Its location on the surface of the α345 hexamer places it in
juxtaposition with the GP epitopes and T-cell receptor epitope
(27, 44–46), based on a predicted α345 hexamer model (22).
The convergence of these pathogenic pathways suggests that a
narrow site on the surface of the α345 hexamer is critical in
pathogenesis of GP and AS; 3) the Z-appendage is a non-
truncating variant, thus can incorporate into the GBM, and 4)
its impact on hexamer function may serve as a vanguard for
understanding the unknown mechanisms of numerous other
variants nearby on the hexamer surface. Collectively, these
features prompted us to assess the pathogenicity of the Z-
appendage in a mouse model and to elucidate the underpin-
ning biology and chemistry by solving the crystal structure and
assembly mechanism of the α345 hexamer.
Generation of the Zurich variant knock-in mouse
To assess pathogenicity, we developed a mouse harboring
the Zurich variant using CRISPR/Cas9 editing technology. To
increase the DNA break efficiency, two overlapping guide
RNAs located within exon 52 of the COL4A3 gene were used.
Each guide RNA consisted of a 20-base DNA stretch
(TCTTCATGCACACCTGACAG and CATGACTTTGTT
ACTTAAGA, boxed in Fig. 3A) directly preceding an NGG as
a proto-spacer adjacent motif. A single-strand oligonucleotide
repair DNA consisting of a 79 base repair fragment core and
flanking 111 and 142 base homology arms was designed
(Fig. 3A). As shown in Figure 3A, mutations were introduced
to substitute His1169 with eight new amino acids:
QQNCYFSS; disrupt the PAM sequences; introduce a unique
NsiI restriction site for genotyping (Fig. 3, B and C); and
eliminate the polyT stretch. Two separate lines were estab-
lished and backcrossed to C57BL6/J mice for four generations
to eliminate possible off target events. Homozygote animals on
C57BL/6 background were then generated and line one was
expanded and studied. Mice were viable, fertile, and born in
the expected Mendelian ratios. For additional details on mouse
genotyping, see Supplementary Section 5 and Figure S5.
Zurich variant phenocopies features of Alport syndrome in a
knock-in mouse (Col4a3z/z), revealing the α345 hexamer as a
focal point in GBM function and dysfunction
Homozygous knock-in mice (Col4a3z/z) on a C57BL6
background were viable, fertile, and born in the expected
Figure 3. Production of the Zurich variant mouse. A, Zurich variant mouse CRISPR/Cas9 design scheme. Guide RNAs consisting of 20 base pairs each are
boxed; break sites are indicated. Lower part shows repair DNA, which introduces new eight amino acids. B, PCR products of 460 bp in wild type (+/+) and
446 bp in the mutant (z/z) were generated using genotyping primers (refer to the Experimental procedures section for the sequences). Mutant PCR product
had NsiI restriction site, while wild type did not. PCR products were then digested with NsiI enzyme resulting in appearance of 300 bp band for the
mutant. Heterozygous (z/+) mice had both undigested and digested bands. C, representative Sanger sequencing of gDNA isolated from homozygous F2
Zurich variant mouse.
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Mendelian ratios. The deposition of collagen IVα345 scaffold to
the GBM assessed by the immunofluorescence was unaffected
in the Col4a3z/z mice. Hexamer formation and cross-linking
was also unaffected. Direct indication that the Z-appendage
incorporated into the scaffold was obtained from the band
shift of the α3 NC1 domain derived from Col4a3z/z mouse
kidney. (Fig. 4 and Supplementary Section 6; Fig. S6).
Histological analysis of kidney sections revealed glomer-
ulosclerosis with rare crescents in homozygous Col4a3z/z mice
(Fig. 4). The GBM was irregular in thickness, lamellated with
occasional splitting and with podocyte foot processes efface-
ment while morphometry revealed substantial and widely
variable GBM thickening (Fig. 4). The majority of Zurich mice
developed moderate albuminuria from 9 to 23 weeks (Fig. 4
and Fig. S7), while two mice displayed a rapid tenfold in-
crease in urine albumin-to-creatinine ratios at 14 to 16 weeks
(Fig. S8), demonstrating variability in the appendage effects.
No circulating α3NC1-specific antibodies were detected
(Fig. S9). Aged heterozygous Col4a3+/z mice also displayed
irregular thickened GBM and mild but significant albuminuria
(Fig. 5). This heterozygous phenotype is distinct from the
heterozygous knock-out model, which lacks the phenotype
(47, 48). The difference highlights the toxicity of the Z-
appendage in the function of the collagen IVα345 scaffold.
Figure 4. Zurich variant knock-in homozygous mouse (Col4a3z/z mouse) phenocopies features of Alport syndrome in GBM. Immunofluorescence
staining of renal sections demonstrates deposition of genetically modified α3 chain along with native α4 and α5 chains within collagen IV α345 scaffold in a
Col4a3z/z mouse (top left). This scaffold did not form in the kidney of Col4a3 KO mouse lacking α3 chain (top left). The Zurich variant also did not interfere
with hexamer assembly and formation of sulfilimine cross-links as shown by western blot using collagen IV chain-specific antibodies (top left, D indicates
dimer and M indicates monomer). The shift in the position of mutant α3 bands relative to the control is due to the difference in sequence length. Samples
were normalized on kidney weight and tubulin (bottom of the western blot). Histological analysis of kidney sections revealed varying degree of glomerular
sclerosis in 20% to 70% of the glomeruli in the Col4a3z/z mice (periodic acid–Schiff (PAS)-stained representative glomeruli are shown, magnification 600×)
and occasional formation of crescents (bottom left, H&E staining). Representative transmission electron microscopy (TEM) images of the glomerular capillary
loops from two different Col4a3z/z mice and a wild-type control mouse are shown at the top right. In Col4a3z/z mice exhibiting high albuminuria (see
corresponding urine albumin-to-creatinine ratio (ACR) values and albumin SDS-PAGE bands above the TEM images), the glomerular basement membrane
(GBM) was irregularly thinned and thickened, lamellated, and occasionally split with foot process effacement. Animals with moderate albuminuria
demonstrated mainly irregular thickening of the GBM (arrows and higher magnification for GBM structure). GBM thickness (measured from two glomeruli
with five images each, from each mouse) was increased in WT (n = 2) versus Col4a3z/z (n = 3) mice (bottom middle) (p < 0.001, Student’s t test). Col4a3z/z
mice (n = 6) had significantly elevated ACR compared with WT mice (n = 5) (bottom right). Both experimental groups included male and female mice.
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Collectively, these findings revealed that the Z-appendage
rendered the α345 hexamer defective causing a wide range of
ultrastructural abnormalities in the GBM, proteinuria, and
glomerulosclerosis. Animals with high level of albuminuria
displayed GBM changes characteristic for AS while moder-
ately affected mice had GBM thickening. The mild phenotype
observed in the heterozygous mice recapitulates the dominant
trait in humans and suggests that defective α345 hexamer
“signals” the pathological changes. In contrast to knock-out
mouse models that eliminate the collagen IVα345 scaffold
from basement membranes, the Zurich mouse provides
trackability to discover functions of the α345 scaffold at a
specific site and to discover pathogenic mechanisms. The
absence of α3NC1 autoantibodies indicates that the
appendage is not causal, but a risk factor in GP disease. The
Z-appendage pathogenicity, in both homozygous and het-
erozygous mice, pinpointed the α345 hexamer as a critical
structure, enabling the GBM to function as a permselective
filter.
Discussion
In the present study of two rare diseases, familial GP and
AS, a genetic collagen IVα345 variant encoding a short 8-
residue appendage, common to both diseases, was found to
serve as a beacon into the inner workings of the GBM. The
appendage is pathogenic in Zurich mice, causing ultrastruc-
tural abnormalities in the GBM, albuminuria, and glomer-
ulosclerosis. These features phenocopied the wide spectrum of
glomerular phenotypes in human AS, which supports the
recent nomenclature of COL4A3, COL4A4, and COL4A5
variants as AS (37). Moreover, the prevalence of the Z-variant
is estimated to be approximately one million people world-
wide, placing them at risk of progressing to renal failure and
developingGP (Fig. 2A).
The crystal structure and assembly mechanisms of the
α345 hexamer, as presented in Boudko et al. (49) and Ped-
chenko et al. (50), provided a framework to interpret how the
Z-appendage, a representative AS variant, played a role in AS
Figure 5. Zurich variant knock-in heterozygous mouse (Col4a3z/+ mouse) shows pathologic phenotype in kidneys at 1 year of age. Histological
analysis of periodic acid–Schiff (PAS)-stained kidney sections (×400) revealed varying degree of glomerular sclerosis (top left). Representative transmission
electron microscopy (TEM) images of the glomerular capillary loops from two different Col4a3z/+ mice and a wild-type control mouse are shown at the
bottom. The glomerular basement membrane (GBM) was irregularly thickened in Col4a3z/+ mice (red arrows; TEM images scale bars are 1 μm). One-year-old
Col4a3z/+ mice (n = 12) exhibited mild albuminuria compared with the age-matched WT mice (n = 9). Albumin-to-creatinine ratios are represented in graph
(top right). Both experimental groups included male and female mice. The p value was 0.04.
EDITORS’ PICK: Pathobiology of collagen IV α345
8 J. Biol. Chem. (2021) 296 100590
Figure 6. Z-appendage can participate in multiple chemical interactions and thus can contribute to AS and GP pathogenesis. A, the Z-appendage is
an 8-residue extension of the α3 chain replacing the C-terminal histidine residue of the native structure. It is located at the apex of α3NC1 monomer, in
juxtaposition with EA and EB hypoepitope loops (left). The appendage is flexible and can assume multiple conformations as predicted by molecular dy-
namics (MD) simulations (left). Z-appendage features a cysteine residue with free sulfhydryl group (middle). This group can participate in multiple reactions
resulting in posttranslational modifications (PTMs), complexes with metal ions or small molecule drugs, and disulfide bonds with proteins (right) (49, 50). B,
the appendage has been predicted to assume multiple configurations (left); not shown is the Z-appendage of the opposing α345 trimer. Because of its
relatively short length, the expected impact of Z-appendage is on the structure and/or function of a specific area within the α345 hexamer including the EA
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and a possible structural risk factor for GP (49, 50). Z-
appendage features a cysteine residue with free sulfhydryl
group. This group can participate in multiple reactions
resulting in posttranslational modifications (PTMs), com-
plexes with metal ions or small molecule drugs, and disulfide
bonds with proteins (Fig. 6A and Boudko et al. 49) (51, 52).
The appendage is juxtaposed with the GP hypoepitopes
forming common “hotspots” of dysfunction, called the LCL
site (49). This convergence of pathogenic pathways indicates
that the LCL site is bioactive, having functions that include
signaling and organizing macromolecular complexes (49,
50). Since the LCL bioactive site is conformationally plastic
(50), its functions can be perturbed by the Z-appendage and
other genetic variants that occur in the hexamer in AS
(Fig. 6B), endogenous and exogenous triggers in GP
(Fig. 6C), and hyperglycemia in DN (Fig. 7 and Boudko et al.
49). Therefore, we conclude that the α345 hexamer is a focal
point with bioactivity, enabling GBM morphology and its
function as a permselective filter, which can be altered in
GBM diseases.
Collectively, these findings demonstrate that the α345 hex-
amer is a promising target for therapeutic intervention.
Attractive therapeutic strategies for AS include protein
replacement and pharmacological chaperones, because the
GBM is directly accessible to protein delivery via the blood-
stream. Recent advances in delivery of full-length recombinant
laminin molecules to the GBM (53) set up a possibility that a
full-length or mini-α345 protomer can be delivered thera-
peutically to the glomerulus, where it can oligomerize forming
the collagen IVα345 scaffold in the GBM (50). Moreover,
because a significant number of hypomorph variants occurs
within the hexamer (49), the multiple pores, crevices, and
cavities of the α345 hexamer can be potential targets for
pharmacological chaperone interventions to correct misfold-
ing or stabilize the protein and reduce degradation. In addi-
tion, the knock-in mouse is a promising model for the
development of new drugs and gene editing therapies for AS.
Experimental procedures
Human subjects
All human studies were done in accordance with the Hel-
sinki Principles. Informed consent was obtained from all pa-
tients included in the studies, and the Institutional Review
Board of the Vanderbilt University Medical Center and the
Cantonal Ethics Committee of Zurich approved this study.
Genomic DNA extraction and library preparation
Genomic DNA from FFPE samples was extracted with
either Covaris of QIAGEN FFPE DNA extraction kits. DNA
from blood cells was extracted with Promega’s Wizard
Genomic DNA kit (cat# A1120).
Whole-genome libraries were prepared from genomic DNA
with the NEBNext Ultra II DNA Library Prep Kit for Illumina
per manufacturer’s instructions. The DNA was fragmented on
the Covaris LE220 targeting an average insert size of 400 to
500 bp. The blunt ends of each sample were end repaired,
adenylated for adaptor ligation, ligated to standard Illumina
adapters, and PCR amplified.
Whole-exome libraries were generated from genomic DNA
extracted from FFPE kidney biopsies using the Exome
captured with IDT xGen Exome Research Panel library (IDT).
Whole-exome and whole-genome data analysis
Both whole exome sequence and whole genome sequence
were subjected to DNA sequencing on the NovaSeq Illumina
platform, and genotype calls were made at targeted bases as
described below (Zurich section). All targeted bases of
COL4A3 exon 52 in WES experiments show ≥20 independent
reads in all samples and were subject for de novo mutation
detection using human reference genome hg19. Average
sequencing depth for all bases in targeted region (COL4A3
exon 52) in WGS experiments was at least ×50.
Library sequencing
Captured libraries were sequenced using the Illumina
NovaSeq 6000 system (Illumina) with paired end reads of
151 bp according to the manufacturer’s protocols. Raw reads
in FASTQ format fromWES or WGS were aligned to the hg19
reference genome using the Burrows–Wheeler Aligner (BWA;
http://bio-bwa.sourceforge.net/). Duplicates were removed
with Picard (http://picard.Sourceforget.net). WES and WGS
data were analyzed using GATK INDEL calling algorithm
(GATK (http://www.broadinstitute.org/gatk/) following the
guidelines provided in the user manuals.
SNPs filtration and annotation
INDELs and the variants were filtered using GATK and
annotated using the ANNOVAR program (http://www.
openbioinformatics.org/annovar/).
Production of reagents for immunoassays of GP patient
autoantibodies
Recombinant human α1-α6NC1 monomers and α3/α1
monomeric chimeras bearing EA and EB regions of α3NC1 were
purified from the culture medium of stably transfected HEK
293 cells using anti-FLAG agarose (31, 54). For the construction
of mutated α3NC1 or α1NC1 domains containing an 8-residue
extension on carboxy termini, we used PCR mutagenesis with
corresponding pRcX expression vectors as template (55).
Introduction of the target mutations was verified by automated
sequencing. Native collagen IV NC1 hexamers were isolated
and EB hypoepitopes and the crevice between them called the loop-crevice-loop (LCL) site. In the pathogenesis of Alport syndrome, Z-appendage can block
the RGD integrin binding site (60) or phosphorylation site (61) located in the adjacent triple helical domain, interfere with the EA and EB hypoepitope loops,
and attract toxic small molecules and metals to the crevice (inset). C, in Goodpasture’s (GP) disease, Z-appendage can sensitized α345 hexamer, a GP
autoantigen, to different second-hit triggers of GP autoantibody production such as environmental toxins or endogenous pathogenic factors, e.g., in-
flammatory response to bacterial infections, glycoxidative stress in diabetes, etc.
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from human and bovine GBM after collagenase digestion (55).
In some experiments, the GBM NC1 hexamers were denatured
by treatment with 6 mol/l guanidine-HCl for 30 min at 60o C
prior to coating on ELISA plates.
NC1 domain isolation from mouse tissues and western
blotting
The kidneys or lungs from wild-type control and homozy-
gous Zurich mutant mice were homogenized using metal bug
Figure 7. The α345 hexamer is a focal point in GBM function and dysfunction with LCL sites as potential therapeutic targets in the treatment of
GBM kidney diseases. The collagen IVα345 scaffold is a major structure underlying glomerular (GBM) basement membrane. In the GBM, it is deposited by
podocytes (62) in the form of protomers that self-assemble in the presence of extracellular levels of chloride ions (63). The scaffold has been defined as a
“smart” scaffold (64) due to the presence of multiple binding sites and surfaces that allow participation in quaternary and quinary interactions (65) within
the crowded macromolecular environment of the insoluble basement membrane. The α345 hexamer is a key connection module within the collagen IVα345
scaffold. The noncollagenous (NC1) domains of individual α-chains forming the hexamer encode its specific composition and assembly via intracellular
trimerization followed by extracellular hexamerization. Quaternary and quinary interactions involving the hexamer surface may include binding partners
within the basement membrane and cell surface receptors inducing signaling. There are functional loop-crevice-loop (LCL) bioactive sites at the apices of
the hexameric structure (indicated by red square brackets) where pathogenic mechanisms for Alport syndrome, Goodpasture’s disease, and potentially
diabetic nephropathy converge. This convergence of pathogenic pathways indicates that the LCL site harbors bioactive functions, including signaling and
organizing macromolecular complexes, which underlie the GBM biology. The LCL sites are targets for genetic variants and toxic triggers causing basement
membrane abnormalities and leading to renal, pulmonary, otic, and eye disorders. Triggers are envisioned as both environmental and endogenous, e.g.,
hyperglycemia in diabetes. The LCL sites and downstream pathways are potential targets for rational design of protein replacement and small-molecule
therapies. For additional details, see Boudko et al. (49), Fig. 6.
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beads homogenizer system in TBS buffer containing 0.1%
Tween 20 (TBST). Beads were centrifuged and precipitated
material was washed with TBST four times. At the final step
precipitate was dissolved in 250 μl of collagenase digestion
buffer (55) containing 100 μg/ml of collagenase and incubated
overnight at 37 C. Soluble portion was loaded and separated
by SDS-PAGE using 4 to 20% gradient gel, transferred to
nitrocellulose membranes for probing with H31, H43, and
Mab5 antibodies.
Mouse tissue immunofluorescence and light microscopy
analysis
Kidneys were cut and dropped into near-freezing pentane
(Fisher Scientific). Lungs were first inflated with 1:1 solution of
optimal cutting temperature compound (Tissue-Tek) and PBS.
For cryosectioning, tissue was embedded into the mold and
4 μm sections were cut with cryostat and placed on slides.
Slides were pretreated with 6 M urea in 0.1 M glycine-HCl
buffer, pH 3.0, for 10 min (24), followed by several washes
with PBS and PBS/0.2% Tween. Slides were preincubated with
10% normal goat serum (Invitrogen) for 1 h at RT to block
nonspecific binding of antibodies. The following primary an-
tibodies were used for antigen detections: rat anti-collagen IV
α3 NC1 (1:250 dilution, H31), rat anti-collagen IV α4 NC1
(1:250 dilution, H43), and mouse anti-collagen IV α5 NC1
(1:250, Mab5). The H31 and H43 antibodies were from Y. Sado
(Shigei Medical Research Institute). The secondary antibodies
used for immunofluorescence detection were Alexa555 goat
anti-rat (1:1000 dilution; Abcam) and Alexa568 goat anti-
mouse (1:1000 dilution; Abcam). All antibodies were diluted
in PBS/0.1% Tween and 5% normal goat serum. Slides were
incubated with primary antibodies overnight at 4 C in a hu-
midified chamber and then washed three times in PBS/0.2%
Tween before incubating with secondary antibodies for 1 h at
RT. Negative control slide was processed similarly to experi-
mental slide, but without primary antibodies.
For light microscopic examination, 5-μm paraffin sections
of the lung tissue (n = 4 for each genotype) were stained with
Periodic acid–Schiff and hematoxylin and eosin. Slides were
reviewed by a pathologist in a blinded fashion and the
morphometric data were acquired and subjectively analyzed.
Morphometric analysis was performed as described previously
(56).
Mouse urine samples collection and ACR measurements
Urine samples were collected according to animal protocol
(M1900063-00) approved by VUMC IACUC. Albumin con-
centrations were measured with Albuwell M kit (Exocell, Inc)
and creatinine concentrations were determined with Creati-
nine Companion kit (Exocell, Inc) according to the protocols
provided by the manufacturer. Electrophoresis SDS-PAGE
analysis of 3 μl urine was also performed on most samples.
Transmission electron microscopy of mouse tissues
Freshly extracted kidneys were cut in small pieces (2 × 2
mm) and fixed in 2.5% glutaraldehyde buffered in 0.1 M
sodium cacodylate buffer, pH 7.5 overnight. Lungs were
inflated with 2 ml of 2% PFA plus 2% glutaraldehyde and left
immersed in the same fixative solution overnight. Small pieces
were cut next day. Tissues were postfixed in 1% osmium te-
troxide, followed by dehydration through a grade series of
ethanol to 100%. Samples were further dehydrated in propyl-
ene oxide and infiltrated and embedded in Spurr’s epoxy. 70-
nm ultrathin sections were collected on 300 mesh copper
grids and stained with 2% uranyl acetate followed by Reynold’s
lead citrate. Stained sections were examined using a T-12
electron microscope (Philips/FEI) operated at 100 kV and
photographed using a 2K camera (AMT).
Expression and purification of α3, α4, and α5 NC1 monomers
Recombinant human NC1 domains were amplified by PCR
from human kidney cDNA library, cloned in derivative of pRc-
CMV mammalian expression vector that includes BM-40
signal peptide and N-terminal FLAG tag, and transfected
into HEK-293 cells using HEPES-calcium phosphate (Pro-
Fection, Promega). Stable clones were selected using neomycin
(0.4 mg/ml) and clones with highest levels of NC1 expression
after testing by western blotting were expanded into T225
culture flasks. Conditioned medium was collected from
confluent cultures two times a week and recombinant proteins
were purified by passing through anti-FLAG M2-agarose
(Sigma) columns with subsequent elution with FLAG peptide
(100 μg/ml, Sigma) and concentration on ultrafiltration con-
centrators (Amicon 10MWCO, Millipore) to 2 to 4 mg/ml.
Proteins were further purified by SEC on Superdex 200 col-
umn in TBS buffer (55).
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